Efeito neuroprotetor do JM-20 em ratos submetidos a traumatismo cranioencefálico leve
Traumatic brain injury (TBI) is a multisystemic pathology with interactions between central nervous system, peripheral nervous system and immune system. It is one of the main causes of death and desability worldwide. The pathophysiology of TBI involves cell death pathways and tissue loss that lead t...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Estado: | Versión publicada |
| Fecha de publicación: | 2021 |
| País: | Brasil |
| Institución: | Universidade Federal de Santa Maria (UFSM) |
| Repositorio: | Manancial - Repositório Digital da UFSM |
| Idioma: | portugués |
| OAI Identifier: | oai:repositorio.ufsm.br:1/24412 |
| Acceso en línea: | http://repositorio.ufsm.br/handle/1/24412 |
| Access Level: | acceso abierto |
| Palabra clave: | Neuroproteção Neurodegeneração Droga multi-alvo Neuroinflamação Disfunção mitocondrial Sobrevivência neuronal Neuroprotection Neurodegeneration Multi-target drug Neuroinflammation Mitochondrial dysfunction Neuronal survival CNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICA |
| Sumario: | Traumatic brain injury (TBI) is a multisystemic pathology with interactions between central nervous system, peripheral nervous system and immune system. It is one of the main causes of death and desability worldwide. The pathophysiology of TBI involves cell death pathways and tissue loss that lead to neurodegeneration and deficits in neurological function. It is estimated that 75 to 90% of TBI cases are classified as mild, and the damage following TBI may be underestimated. Despite the large numbers of TBI cases, there is no effective pharmacological treatment available. This study aimed to investigate the effects on TBI outcomes of the new hybrid molecule 3-ethoxycarbonyl-2-methyl-4-(2-nitrophenyl)-4,11-dihydro1H-pyrido[2,3-b][1,5]benzodiazepine (JM-20). JM-20 emerge as a neuroprotective drug because it targets mediators involved in cell death events: calcium channels, due to the dihydropyridine portion; and GABAa receptors, due to benzodiazepine action. Male Wistar rats were submitted to a weight drop model of mild TBI and treated with a single dose of JM-20 (8 mg/kg). 24 h following TBI, JM-20 treatment was able to attenuate locomotor and short-term memory deficits; decrease brain edema; avoid the exacerbated activation of glial cells and consequently the pro-inflammatory signaling by decreasing release of pro-inflammatory cytokines and higher release of neurotrophins; avoid mitochondrial dysfunction through increased oxygen flux consumption in oxidative phosphorylation, and then, improve mitochondrial functionality; JM-20 treatment was also able to mantain the activation of an important pathway related to cellular cascades. Based on these, is possible to confirm that JM-20 has neuroprotective effects by modulating important secondary injury targets and corroborate our hypothesis that JM-20 may become a promising treatment strategy to TBI. |
|---|